Volume : 08, Issue : 06, June – 2021

Title:

19.EPIDERMOLYSIS BULLOSA ACQUISITA-LIKE CUTANEOUS REACTION REPORTED AFTER THE 2ND DOSE OF PFIZER-BIONTECH COVID-19 VACCINATION: A CASE REPORT

Authors :

Ahlam Al-Zahrani,MD, Bassam K Alhallani,MD, Ahmed Darwish,MD, Abdulrahman Al-Bahlool,MD, Abdullah Al-Badri,MD, Zeyad Helmy,MD

Abstract :

Although they are poorly investigated, cutaneous reactions to messenger RNA (mRNA)-based COVID-19 vaccinations have been documented. In this case report, we presented a case of cutaneous EBA-like response following the second shot of the Pfizer COVID vaccine in a 58-year-old woman with no previous chronic health conditions. The clinical picture showed skin rash with mild itching, burning sensation, and mild redness over her hands and face. On the 2nd day, large, tense blisters were developed. There were multiple eroded flaccid bullae with crusts; some were healed with hypopigmentation over the upper parts of the dorsal surface of the hands and feet. The histopathological report showed sub-epidermal cleft, re- epithelization, characteristic fibrinoid necrosis at the blister base, and no inflammatory cells. The patient’s condition has improved on the administration of Prednisolone within eight weeks.
Keywords: Epidermolysis Bullosa Acquisita; COVID-19, Vaccination, Pfizer BioNTech.

Cite This Article:

Please cite this article in press Ahlam Al-Zahrani et al., Epidermolysis Bullosa Acquisita-Like Cutaneous Reaction Reported After The 2nd Dose Of Pfizer-Biontech Covid-19 Vaccination: A Case Report., Indo Am. J. P. Sci, 2021; 08(06).

Number of Downloads : 10

References:

1. World Health Organization. Novel Coronavirus (2019-nCoV), Situation Report – 1. https://www.who.int/docs/default-source/coronaviruse/situation- reports/20200121-sitrep-1-2019-ncov.pdf [Accessed at 1 June 2021].
2. Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death & Differentiation. 2021 Feb;28(2):626-39.
3. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine—United States, December 2020. Morbidity and Mortality Weekly Report. 2020 Dec 18;69(50):1922.
4. COVID C, Team R. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. Morbidity and Mortality Weekly Report. 2021 the 15th of January;70(2):46.
5. Gammon WR, Briggaman RA, Woodley DT, Heald PW, Wheeler Jr CE. Epidermolysis bullosa acquisita—a pemphigoid-like disease. Journal of the American Academy of Dermatology. 1984 Nov 1;11(5):820-32.
6. Kasperkiewicz M, Sadik CD, Bieber K, Ibrahim SM, Manz RA, Schmidt E, Zillikens D, Ludwig RJ. Epidermolysis bullosa acquisita: from pathophysiology to novel therapeutic options. Journal of Investigative Dermatology. 2016 the 1st of January;136(1):24-33.
7. Iwata H, Vorobyev A, Koga H, Recke A, Zillikens D, Prost-Squarcioni C, Ishii N, Hashimoto T, Ludwig RJ. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet journal of rare diseases. 2018 Dec;13(1):1-9.
8. Licarete E, Ganz S, Recknagel MJ, Di Zenzo G, Hashimoto T, Hertl M, Zambruno G, Hundorfean G, Mudter J, Neurath MF, Bruckner-Tuderman L. Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC immunology. 2012 Dec;13(1):1-0.
9. Elliott GT. Two cases of epidermolysis bullosa. J Cutan Genitourin Dis. 1895;13:10.
10. Roenigk HH, Ryan JG, Bergfeld WF. Epidermolysis bullosa acquisita: report of three cases and review of all published cases. Archives of dermatology. 1971 the 1st of January;103(1):1-0.
11. Richter BJ, McNutt NS. The spectrum of epidermolysis bullosa acquisita.
Archives of dermatology. 1979 Nov 1;115(11):1325-8.
12. Caux F. Diagnosis and clinical features of epidermolysis bullosa acquisita. Dermatologic clinics. 2011 the 1st of July;29(3):485-91.
13. Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT. Guillain-Barré syndrome following influenza vaccination. Jama. 2004 Nov 24;292(20):2478-81.
14. The New York Times. A Few Covid Vaccine Recipients Developed a Rare Blood Disorder”. Feb 2021. [Accessed the 2nd of June 2021].
15. American Society of Hematology. “COVID-19 resources”. [Accessed the 2nd of June 2021].
16. Forni G, Mantovani A, Moretta L, Rezza G Vaccines. Accademia Nazionale dei Lincei. 2018. Available at: https://www.lincei.it/it/article/i-vaccini- vaccines-position-paper [Accessed 2 June 2021].